Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Ann Dyslexia ; 67(3): 333-355, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29134484

RESUMEN

The importance of feedback for learning has been firmly established over the past few decades. The question of whether feedback plays a significant role in the statistical learning abilities of adults with dyslexia, however, is currently unresolved. Here, we examined the role of feedback in grammaticality judgment, type of structural knowledge, and confidence rating in both typically developed and dyslexic adults. We implemented two artificial grammar learning experiments: implicit and explicit. The second experiment was directly analogous to the first experiment in all respects except training format: the standard memorization instruction was replaced with an explicit rule-search instruction. Each experiment was conducted with and without performance feedback. While both groups showed significantly improved learning in the feedback-based explicit artificial grammar learning task, only the typically developed adults demonstrated higher levels of conscious structural knowledge. The present study demonstrates that the basis for the grammaticality judgment of adults with dyslexia differs from that of typically developed adults, regardless of increase in the level of explicitness.


Asunto(s)
Biorretroalimentación Psicológica/métodos , Dislexia/psicología , Aprendizaje/fisiología , Lectura , Adulto , Biorretroalimentación Psicológica/fisiología , Dislexia/diagnóstico , Dislexia/fisiopatología , Femenino , Humanos , Juicio/fisiología , Lingüística , Masculino , Adulto Joven
2.
J Control Release ; 191: 90-97, 2014 Oct 10.
Artículo en Inglés | MEDLINE | ID: mdl-25051221

RESUMEN

There is an unmet need for efficient near-infrared photothermal transducers for the treatment of highly aggressive cancers and large tumors where the penetration of light can be substantially reduced, and the intra-tumoral nanoparticle transport is restricted due to the presence of hypoxic or necrotic regions. We report the performance advantages obtained by sub 100nm gold nanomatryushkas, comprising concentric gold-silica-gold layers compared to conventional ~150nm silica core gold nanoshells for photothermal therapy of triple negative breast cancer. We demonstrate that a 33% reduction in silica-core-gold-shell nanoparticle size, while retaining near-infrared plasmon resonance, and keeping the nanoparticle surface charge constant, results in a four to five fold tumor accumulation of nanoparticles following equal dose of injected gold for both sizes. The survival time of mice bearing large (>1000mm(3)) and highly aggressive triple negative breast tumors is doubled for the nanomatryushka treatment group under identical photo-thermal therapy conditions. The higher absorption cross-section of a nanomatryoshka results in a higher efficiency of photonic to thermal energy conversion and coupled with 4-5× accumulation within large tumors results in superior therapy efficacy.


Asunto(s)
Oro/administración & dosificación , Hipertermia Inducida/métodos , Nanocáscaras , Fototerapia/métodos , Neoplasias de la Mama Triple Negativas/terapia , Animales , Línea Celular Tumoral , Femenino , Oro/química , Humanos , Hipertermia Inducida/instrumentación , Inyecciones Intravenosas , Láseres de Semiconductores , Ratones , Ratones Desnudos , Nanomedicina/métodos , Tamaño de la Partícula , Fototerapia/instrumentación , Polietilenglicoles/química , Dióxido de Silicio/química , Propiedades de Superficie , Factores de Tiempo , Transductores , Neoplasias de la Mama Triple Negativas/patología , Carga Tumoral , Ensayos Antitumor por Modelo de Xenoinjerto
3.
Breast Cancer Res Treat ; 125(1): 27-34, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20217215

RESUMEN

Trastuzumab is a FDA-approved drug that has shown clinical efficacy against HER2+ breast cancers and is commonly used in combination with other chemotherapeutics. However, many patients are innately resistant to trastuzumab, or will develop resistance during treatment. Alternative treatments are needed for trastuzumab-resistant patients. Here, we investigate gold nanoparticle-mediated photothermal therapies as a potential alternative treatment for chemotherapy-resistant cancers. Gold nanoshell photothermal therapy destroys the tumor cells using heat, a physical mechanism, which is able to overcome the cellular adaptations that bestow trastuzumab resistance. By adding anti-HER2 to the gold surface of the nanoshells as a targeting modality, we increase the specificity of the nanoshells for HER2+ breast cancer. Silica-gold nanoshells conjugated with anti-HER2 were incubated with both trastuzumab-sensitive and trastuzumab-resistant breast cancer cells. Nanoshell binding was confirmed using two-photon laser scanning microscopy, and the cells were then ablated using a near-infrared laser. We demonstrate the successful targeting and ablation of trastuzumab-resistant cells using anti-HER2-conjugated silica-gold nanoshells and a near-infrared laser. This study suggests potential for applying gold nanoshell-mediated therapy to trastuzumab-resistant breast cancers in vivo.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Antineoplásicos/farmacología , Neoplasias de la Mama/patología , Resistencia a Antineoplásicos , Oro , Inmunoconjugados/farmacología , Terapia por Láser , Nanocáscaras , Fototerapia/métodos , Receptor ErbB-2/antagonistas & inhibidores , Anticuerpos Monoclonales Humanizados , Neoplasias de la Mama/inmunología , Neoplasias de la Mama/metabolismo , Muerte Celular , Línea Celular Tumoral , Femenino , Citometría de Flujo , Humanos , Microscopía Confocal , Receptor ErbB-2/inmunología , Receptor ErbB-2/metabolismo , Trastuzumab
4.
Breast Cancer Res ; 5(5): 228-31, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12927029

RESUMEN

Intensive basic and clinical research over the past 20 years has yielded crucial molecular understanding into how estrogen and the estrogen receptor act to regulate breast cancer and has led to the development of more effective, less toxic, and safer hormonal therapy agents for breast cancer management and prevention. Selective potent aromatase inhibitors are now challenging the hitherto gold standard of hormonal therapy, the selective estrogen-receptor modulator tamoxifen. Furthermore, new selective estrogen-receptor modulators such as arzoxifene, currently under clinical development, offer the possibility of selecting one with a more ideal pharmacological profile for treatment and prevention of breast cancer. Two recent studies in preclinical model systems that evaluate mechanisms of action of these new drugs and suggestions about their optimal clinical use are discussed.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Inhibidores de la Aromatasa , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/prevención & control , Drogas en Investigación/uso terapéutico , Moduladores de los Receptores de Estrógeno/uso terapéutico , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Neoplasias Mamarias Experimentales/enzimología , Animales , Neoplasias de la Mama/enzimología , Evaluación Preclínica de Medicamentos , Humanos , Neoplasias Mamarias Experimentales/prevención & control , Ratones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA